Jean C Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6268930/publications.pdf

Version: 2024-02-01

80 papers	5,905 citations	66315 42 h-index	76872 74 g-index
85 all docs	85 docs citations	85 times ranked	6078 citing authors

#	Article	IF	Citations
1	Staphylococcus aureus Extracellular Vesicles: A Story of Toxicity and the Stress of 2020. Toxins, 2021, 13, 75.	1.5	34
2	IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus. Frontiers in Immunology, 2021, 12, 624310.	2.2	17
3	A functional menadione biosynthesis pathway is required for capsule production by Staphylococcus aureus. Microbiology (United Kingdom), 2021, 167, .	0.7	11
4	Orchestration of human macrophage NLRP3 inflammasome activation by Staphylococcus aureus extracellular vesicles. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3174-3184.	3.3	100
5	Revisiting the regulation of the capsular polysaccharide biosynthesis gene cluster in Staphylococcus aureus. Molecular Microbiology, 2019, 112, 1083-1099.	1.2	17
6	Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform. Nature Communications, 2018, 9, 1379.	5.8	213
7	Optimization of Stress-Based Microfluidic Testing for Methicillin Resistance in Staphylococcus aureus Strains. Diagnostics, 2018, 8, 24.	1.3	2
8	Evaluation of serotypes 5 and 8 capsular polysaccharides in protection againstStaphylococcus aureusin murine models of infection. Human Vaccines and Immunotherapeutics, 2017, 13, 1609-1614.	1.4	10
9	Antibodies toStaphylococcus aureuscapsular polysaccharides 5 and 8 perform similarlyin vitrobut are functionally distinctin vivo. Virulence, 2017, 8, 859-874.	1.8	15
10	Rapid phenotypic stress-based microfluidic antibiotic susceptibility testing of Gram-negative clinical isolates. Scientific Reports, 2017, 7, 8031.	1.6	24
11	Murine Models of Bacteremia and Surgical Wound Infection for the Evaluation of Staphylococcus aureus Vaccine Candidates. Methods in Molecular Biology, 2016, 1403, 409-418.	0.4	4
12	The biochemical origins of the surface-enhanced Raman spectra of bacteria: a metabolomics profiling by SERS. Analytical and Bioanalytical Chemistry, 2016, 408, 4631-4647.	1.9	194
13	Rapid Detection of Bacteria from Blood with Surface-Enhanced Raman Spectroscopy. Analytical Chemistry, 2016, 88, 8026-8035.	3.2	89
14	Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections. Vaccine, 2016, 34, 6402-6407.	1.7	41
15	Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus. Scientific Reports, 2016, 6, 25063.	1.6	77
16	Microbial sphingomyelinase induces RhoA-mediated reorganization of the apical brush border membrane and is protective against invasion. Molecular Biology of the Cell, 2016, 27, 1120-1130.	0.9	5
17	Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection. MBio, 2016, 7, e02232-15.	1.8	24
18	The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis. Microbiology (United Kingdom), 2016, 162, 1185-1194.	0.7	50

#	Article	IF	Citations
19	Dynamic in vivo mutations within the ica operon during persistence of Staphylococcus aureus in the airways of cystic fibrosis patients. PLoS Pathogens, 2016, 12, e1006024.	2.1	50
20	Phenotypic heterogeneity and temporal expression of the capsular polysaccharide in <scp>S</scp>taphylococcus aureus. Molecular Microbiology, 2015, 98, 1073-1088.	1.2	27
21	Staphylococcus aureus Colonization of the Mouse Gastrointestinal Tract Is Modulated by Wall Teichoic Acid, Capsule, and Surface Proteins. PLoS Pathogens, 2015, 11, e1005061.	2.1	46
22	USA300 and USA500 Clonal Lineages of Staphylococcus aureus Do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the cap5 Locus. MBio, 2015, 6, .	1.8	82
23	Structure and Function of Surface Polysaccharides of Staphylococcus aureus. Current Topics in Microbiology and Immunology, 2015, 409, 57-93.	0.7	35
24	Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. Journal of Antimicrobial Chemotherapy, 2015, 70, 1453-1465.	1.3	122
25	Staphylococcus aureusgene expression in a rat model of infective endocarditis. Genome Medicine, 2014, 6, 93.	3.6	23
26	Protein Antigens Increase the Protective Efficacy of a Capsule-Based Vaccine against Staphylococcus aureus in a Rat Model of Osteomyelitis. Infection and Immunity, 2014, 82, 83-91.	1.0	31
27	Prevention of Staphylococcus aureus Infections by Glycoprotein Vaccines Synthesized in Escherichia coli. Journal of Infectious Diseases, 2014, 209, 1551-1561.	1.9	114
28	Antibodies to Staphylococcus aureus Serotype 8 Capsular Polysaccharide React with and Protect against Serotype 5 and 8 Isolates. Infection and Immunity, 2014, 82, 5049-5055.	1.0	14
29	Analysis of the Staphylococcus aureus capsule biosynthesis pathway in vitro: Characterization of the UDP-GlcNAc C6 dehydratases CapD and CapE and identification of enzyme inhibitors. International Journal of Medical Microbiology, 2014, 304, 958-969.	1.5	22
30	Stress-induced Antibiotic Susceptibility Testing on a Chip. Journal of Visualized Experiments, 2014, , e50828.	0.2	4
31	Production of capsular polysaccharide does not influence Staphylococcus aureusvancomycin susceptibility. BMC Microbiology, 2013, 13, 65.	1.3	31
32	Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation. International Journal of Medical Microbiology, 2013, 303, 685-692.	1.5	83
33	Novel Synthetic (Poly)Glycerolphosphate-Based Antistaphylococcal Conjugate Vaccine. Infection and Immunity, 2013, 81, 2554-2561.	1.0	16
34	Staphylococcus aureus NorD, a Putative Efflux Pump Coregulated with the Opp1 Oligopeptide Permease, Contributes Selectively to Fitness In Vivo. Journal of Bacteriology, 2012, 194, 6586-6593.	1.0	40
35	A microfluidic platform for rapid, stress-induced antibiotic susceptibility testing of Staphylococcus aureus. Lab on A Chip, 2012, 12, 4523.	3.1	59
36	Opsonic and Protective Properties of Antibodies Raised to Conjugate Vaccines Targeting Six Staphylococcus aureus Antigens. PLoS ONE, 2012, 7, e46648.	1.1	47

#	Article	IF	Citations
37	Reduced Neutrophil Apoptosis in Diabetic Mice during Staphylococcal Infection Leads to Prolonged Tnfl± Production and Reduced Neutrophil Clearance. PLoS ONE, 2011, 6, e23633.	1.1	66
38	The effectiveness of the controlled release of gentamicin from polyelectrolyte multilayers in the treatment of Staphylococcus aureus infection in a rabbit bone model. Biomaterials, 2010, 31, 6019-6030.	5.7	147
39	The Zwitterionic Cell Wall Teichoic Acid of Staphylococcus aureus Provokes Skin Abscesses in Mice by a Novel CD4+ T-Cell-Dependent Mechanism. PLoS ONE, 2010, 5, e13227.	1.1	32
40	Characterization of the Structure and Biological Functions of a Capsular Polysaccharide Produced by Staphylococcus saprophyticus. Journal of Bacteriology, 2010, 192, 4618-4626.	1.0	22
41	Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. Journal of Clinical Investigation, 2010, 120, 3220-3233.	3.9	57
42	Defects in Innate Immunity Predispose C57BL/6J-Lepr^{db}/Lepr^{db}Mice to Infection byStaphylococcus aureus. Infection and Immunity, 2009, 77, 1008-1014.	1.0	102
43	Staphylococcal Vaccines and Immunotherapies. Infectious Disease Clinics of North America, 2009, 23, 153-171.	1.9	82
44	Intrafamilial outbreak of subcutaneous abscesses caused by PVL-positive methicillin-sensitive Staphylococcus aureus. Journal of Infection, 2008, 57, 278-280.	1.7	7
45	Vaccination and passive immunisation against Staphylococcus aureus. International Journal of Antimicrobial Agents, 2008, 32, S71-S78.	1.1	111
46	IFN-Î³ Regulated Chemokine Production Determines the Outcome of Staphylococcus aureus Infection. Journal of Immunology, 2008, 181, 1323-1332.	0.4	97
47	Structural and Biological Characterization of a Capsular Polysaccharide Produced by Staphylococcus haemolyticus. Journal of Bacteriology, 2008, 190, 1649-1657.	1.0	26
48	Comparison of Virulence in Communityâ€Associated Methicillinâ€ResistantStaphylococcus aureusPulsotypes USA300 and USA400 in a Rat Model of Pneumonia. Journal of Infectious Diseases, 2008, 198, 561-570.	1.9	182
49	NorB, an Efflux Pump in Staphylococcus aureus Strain MW2, Contributes to Bacterial Fitness in Abscesses. Journal of Bacteriology, 2008, 190, 7123-7129.	1.0	135
50	Antibodies to Capsular Polysaccharide and Clumping Factor A Prevent Mastitis and the Emergence of Unencapsulated and Small-Colony Variants ofStaphylococcus aureusin Mice. Infection and Immunity, 2008, 76, 5738-5744.	1.0	53
51	Capsular Polysaccharide Masks Clumping Factor Aâ€“Mediated Adherence ofStaphylococcus aureusto Fibrinogen and Platelets. Journal of Infectious Diseases, 2007, 196, 919-927.	1.9	55
52	Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Molecular Microbiology, 2006, 59, 948-960.	1.2	72
53	Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model. Infection and Immunity, 2006, 74, 2145-2153.	1.0	139
54	CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10408-10413.	3.3	104

#	Article	IF	Citations
55	Capsule-Negative Staphylococcus aureus Induces Chronic Experimental Mastitis in Mice. Infection and Immunity, 2005, 73, 7932-7937.	1.0	69
56	Staphylococcus aureus Strains That Express Serotype 5 or Serotype 8 Capsular Polysaccharides Differ in Virulence. Infection and Immunity, 2005, 73, 3502-3511.	1.0	115
57	The Pathogenesis of Staphylococcus aureus Infection in the Diabetic NOD Mouse. Diabetes, 2005, 54, 2904-2910.	0.3	64
58	Whole-Genome Sequencing of Staphylococcus haemolyticus Uncovers the Extreme Plasticity of Its Genome and the Evolution of Human-Colonizing Staphylococcal Species. Journal of Bacteriology, 2005, 187, 7292-7308.	1.0	306
59	Pathogenesis of disease. , 2004, , 177-236.		4
60	Staphylococcus aureus Capsular Polysaccharides. Clinical Microbiology Reviews, 2004, 17, 218-234.	5.7	499
61	Three Highly Conserved Proteins Catalyze the Conversion of UDP-N-acetyl-d-glucosamine to Precursors for the Biosynthesis of O Antigen in Pseudomonas aeruginosaO11 and Capsule in Staphylococcus aureus Type 5. Journal of Biological Chemistry, 2003, 278, 3615-3627.	1.6	96
62	Staphylococcus aureus Vaccine. , 2003, , 283-293.		3
63	Regulation of Staphylococcus aureus Capsular Polysaccharide Expression by agr and sarA. Infection and Immunity, 2002, 70, 444-450.	1.0	78
64	Capsule and Vaccine Development. Infectious Agents and Pathogenesis, 2001, , 49-66.	0.1	1
65	Development of antistaphylococcal vaccines. Current Infectious Disease Reports, 2001, 3, 517-524.	1.3	8
66	Staphylococcus aureus Cap5O Has UDP-ManNAc Dehydrogenase Activity and Is Essential for Capsule Expression. Infection and Immunity, 2001, 69, 917-923.	1.0	65
67	Adherence of Staphylococcus aureus to Endothelial Cells: Influence of Capsular Polysaccharide, Global Regulator agr , and Bacterial Growth Phase. Infection and Immunity, 2000, 68, 4865-4871.	1.0	117
68	Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2000, 44, 272-277.	1.4	108
69	Vaccine potential of poly-1-6 Î²-d-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis. Journal of Biotechnology, 2000, 83, 37-44.	1.9	60
70	Broadly Protective Vaccine for Staphylococcus aureus Based on an in Vivo-Expressed Antigen. Science, 1999, 284, 1523-1527.	6.0	339
71	Development and Characterization of a Staphylococcus aureus Nasal Colonization Model in Mice. Infection and Immunity, 1999, 67, 5001-5006.	1.0	114
72	Staphylococcus aureus cap5P Encodes a UDP- N -Acetylglucosamine 2-Epimerase with Functional Redundancy. Journal of Bacteriology, 1999, 181, 4818-4824.	1.0	38

#	Article	IF	Citations
73	Capsular polysaccharides of Staphylococcus aureus. , 1999, , 185-205.		20
74	Identification of a gene essential for O-acetylation of theStaphylococcus aureustype 5 capsular polysaccharide. Molecular Microbiology, 1998, 27, 9-21.	1.2	63
75	Staphylococcus aureusSerotype 5 Capsular Polysaccharide Is Antiphagocytic and Enhances Bacterial Virulence in a Murine Bacteremia Model. Infection and Immunity, 1998, 66, 5183-5189.	1.0	221
76	Staphylococcus aureus cap5O and cap5P Genes Functionally Complement Mutations Affecting Enterobacterial Common-Antigen Biosynthesis in Escherichia coli. Journal of Bacteriology, 1998, 180, 403-406.	1.0	17
77	The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology (United Kingdom), 1997, 143, 2395-2405.	0.7	165
78	Electrotransformation of Staphylococci. , 1995, 47, 209-216.		51
79	Production of Toxic Shock Syndrome Toxin 1 in a Mouse Model of Staphylococcus aureus Abscess Formation. Clinical Infectious Diseases, 1989, 11, S254-S259.	2.9	4
80	Staphylococcal Capsule. , 0, , 456-463.		8